# Metabolic Peptide FAQ — AOD-9604, Tesamorelin, MOTS-c — Raw Wholesale Peptides

> Frequently asked questions about three Metabolic & Weight Research peptides — AOD-9604, Tesamorelin, and MOTS-c — answered directly from the peer-reviewed literature, with citations.

Direct, citation-anchored answers to the questions readers most often bring to these three metabolic research peptides.

## What is AOD-9604?

AOD-9604 is a synthetic sixteen-amino-acid peptide modelled on the C-terminal lipolytic domain of human growth hormone. Its full name is Anti-Obesity Drug 9604. It was engineered to isolate hGH's fat-metabolism effects while avoiding the growth-promoting, IGF-1-elevating, and diabetogenic effects of the intact hormone [6]. It does not bind the growth hormone receptor. Non-clinical evaluation found no genotoxic or toxicological concerns after chronic administration in rodents and primates, with a very short IV half-life of approximately 3 minutes [2].

## What does the peptide AOD-9604 do?

In rodent and cell models, AOD-9604 inhibits acetyl-CoA carboxylase (the rate-limiting enzyme of fatty-acid synthesis) via a membrane-derived second messenger [7], and up-regulates beta-3 adrenergic receptor expression in white adipose tissue, increasing fat oxidation and reducing body fat [4][5]. In the human obesity programme, it did not produce statistically significant weight loss versus placebo across approximately 900 subjects and up to 24-week treatment durations [3]. The rodent fat-metabolism mechanisms have not translated into a demonstrated human fat-loss effect.

## Does AOD-9604 actually work?

In obese mice: yes, it reduced body fat and increased fat oxidation, and the effect required functional beta-3 adrenergic signaling [4]. In approximately 900 obese humans across roughly six oral clinical trials: no statistically significant weight loss was demonstrated versus placebo, and the development programme was discontinued [3]. Tolerability in humans was indistinguishable from placebo — the compound appeared safe in that sense — but safety is not the same as efficacy. Community reports largely reflect the clinical data: most people do not see meaningful fat reduction. This desk does not advise on use.

## How does AOD-9604 work?

Two mechanisms are documented. First, the hGH C-terminal sequence (which includes the AOD-9604 region) inhibits acetyl-CoA carboxylase, reducing de novo fatty-acid synthesis via a second messenger that increases enzyme phosphorylation — an antilipogenic mechanism established in adipocyte and hepatocyte preparations in 1983 [7]. Second, chronic treatment up-regulates beta-3 adrenergic receptor expression in white adipose tissue; the sustained body-weight and fat-loss effects in mice required functional beta3-AR, while an acute fat-oxidation effect did not [4]. In humans, neither mechanism has been confirmed to produce meaningful weight loss [3].

## What is tesamorelin?

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH), bearing an N-terminal modification that confers resistance to the plasma enzyme DPP-IV, extending its half-life relative to native GHRH. It is 44 amino acids long. By binding the GHRH receptor on pituitary somatotrophs, it stimulates synthesis and pulsatile secretion of endogenous growth hormone [12]. It holds an FDA approval (NDA 022505, November 2010) to reduce excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy [9] — a specific patient population, not a general fat-loss indication.

## What does tesamorelin do?

Tesamorelin stimulates the pituitary to release growth hormone in a more physiological pulsatile pattern. The resulting GH drives hepatic production of IGF-1; together GH and IGF-1 promote lipolysis preferentially in visceral adipose tissue. In its approved indication, this produces a sustained reduction in visceral fat of roughly 18% over 52 weeks [12] and a treatment effect of -42 cm2 versus placebo in a JAMA randomized trial [10]. A 2026 meta-analysis of five RCTs confirmed reductions in VAT (-27.71 cm2), trunk fat (-1.18 kg), and hepatic fat (-4.28%), with increased lean mass (+1.42 kg) [8]. These results are all in HIV-infected adults on antiretroviral therapy.

## How does tesamorelin work?

Tesamorelin binds the GHRH receptor on anterior-pituitary somatotroph cells, activating the Gs/adenylyl-cyclase/cAMP/PKA cascade and stimulating pulsatile GH secretion. GH then promotes hepatic IGF-1 synthesis, and the GH/IGF-1 combination drives lipolysis in visceral adipose tissue. In a 2-week study in 13 healthy men, tesamorelin 2 mg/day raised mean overnight GH by 0.5 ug/L (P=0.004) and IGF-1 by 181 ug/L (P<0.0001) without significantly affecting insulin-stimulated glucose uptake [11]. Because it amplifies the body's own GH axis rather than supplying exogenous GH, its profile differs from recombinant human growth hormone.

## Will tesamorelin help me lose belly fat?

The controlled evidence for tesamorelin reducing visceral fat is in HIV-infected adults on antiretroviral therapy with lipodystrophy — that is the population the pivotal trials enrolled and the FDA approved it for [9][12]. Whether it reduces visceral fat in people without HIV or lipodystrophy is mechanistically plausible but has not been established in large randomized controlled trials. It is a prescription drug outside its approved indication, and research-grade material is not approved for human self-administration. This desk does not advise on use and lists no human dose.

## What does the MOTS-c peptide do?

In mice and cell models, MOTS-c inhibits the folate cycle and de novo purine biosynthesis, raises AICAR, and activates AMPK — improving glucose handling and insulin sensitivity in skeletal muscle [15]. It also directly binds and activates casein kinase 2 (CK2) with tissue-specific effects on muscle glucose uptake and atrophy prevention [13]. Under metabolic stress it translocates from the mitochondrion to the nucleus to regulate gene expression through NRF2 and antioxidant-response pathways [17]. Exercise induces endogenous MOTS-c, and exogenous MOTS-c enhanced physical performance in aged mice [16]. Human efficacy has not been established in clinical trials.

## What are the negative side effects of MOTS-c?

Published human safety data for exogenous MOTS-c do not exist — there are no completed human clinical trials, so adverse effects in people are unknown. The literature notes several concerns: no validated human pharmacokinetics (rodent doses cannot be extrapolated), ancestry-dependent genetic variation in response (a pro-diabetogenic mtDNA variant m.1382A>C exists), and research-chemical supply chains with no pharmaceutical-grade purity oversight [15]. Anti-doping authorities treat MOTS-c as a prohibited substance, so athletes who use it face sanctions. Without human clinical data, it is not possible to characterize a human side-effect profile from the peer-reviewed record.

## Is MOTS-c legal to buy?

MOTS-c is not a DEA-controlled substance and is sold by chemical research suppliers in jurisdictions where possession of research chemicals is permitted. It is not FDA-approved for human use, and research-grade material is legally sold as a laboratory research chemical only — not as a medicine, supplement, or food product. For competitive athletes, it is a different matter: WADA and national anti-doping authorities treat MOTS-c under hormone-and-metabolic-modulator prohibition categories, and use by athletes can result in sanctions. Regulatory status varies by jurisdiction; consult applicable local law.

## How often do you inject MOTS-c?

This site does not advise on human dosing, scheduling, or administration of any compound. Dosing and frequency information exists only from rodent studies, where intraperitoneal administration at 0.5-15 mg/kg/day was used in the efficacy work [16]. No peer-reviewed literature has established a human dose, frequency, or administration route. Research-grade MOTS-c is not intended for human consumption. For any health condition, consult a licensed clinician.

---

A precision literature digest — what the studies actually show, in the species they actually studied.